Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Tenvie Therapeutics has dosed the first participant in a Phase 1 trial of TNV313, an orally administered small molecule designed to inhibit NLRP3 and cross the blood-brain barrier. The ascending-dose study in healthy volunteers will assess safety, pharmacokinetics, central nervous system distribution and exploratory pharmacodynamic biomarkers, with preliminary data expected in the first half of 2027. NLRP3-driven inflammatory signaling is implicated in neurodegenerative, cardiometabolic and ophthalmic disease, making brain-accessible inhibition a target of interest for age-related decline.
Digbi Health has extended its precision telehealth platform to all 50 states, combining genetic, gut microbiome, blood biomarker and continuous glucose data into individualized metabolic care plans that may include GLP-1 medications or hormone replacement. Peer-reviewed analysis across seven self-insured employers reported a $3,012 annual reduction in medical spend per member. The model positions multi-signal personalization — rather than single-drug prescribing — as the organizing principle of metabolic care at employer scale.
Inmune Bio and Quantum Computing Inc. will apply quantum optimization, AI and data analytics to clinical datasets spanning preclinical work through four trials of XPro, an investigational selective inhibitor of soluble tumor necrosis factor. The objective is to identify additional diseases and biomarkers driven by the same inflammatory biology the drug targets, beginning with rare diseases that permit smaller, faster trials. Outputs from the Dirac-3S machine will be benchmarked against conventional statistical and machine learning approaches.
Reviewers in Biology propose SIRT1 functional reserve — the remaining operational flexibility of SIRT1-dependent responses under a defined stress load — as a more meaningful measure than static SIRT1 or NAD+ levels. Total cellular NAD+ obscures compartment-specific availability, and total SIRT1 obscures the accumulation of less functional v2 and v3 isoforms with age, which may account for the modest results of supplementation trials aimed at raising these molecules.
Reservoir, a venture from the team behind Cellino, now offers adults cryopreservation of their own peripheral blood mononuclear cells — roughly five vials of five million cells each, collected via a standard 60-milliliter blood draw and stored below −150°C. The underlying premise is that immune cells accumulate age-related changes, including loss of naive T cells and expansion of mutated clones, so earlier samples may be more useful starting material. Whether banked cells of this quantity can serve future autologous therapies remains undetermined, as current CAR-T manufacturing typically relies on far larger apheresis collections.
Diagnostic Imaging Centers of Texas is adding VoxNeuro's FDA-cleared EEG-based Cognitive Function Neuroimaging to its MRI and CT services, pairing structural scans with an objective measure of how the brain responds during attention and memory tasks. The event-related potential analysis is completed in a single visit and cleared for prescription use in adults aged 18 to 70, without providing diagnosis or clinical interpretation. No outcome data has been published on whether the test alters treatment decisions or recovery trajectories.
A Lancet Neurology study measuring 130 blood proteins across 2,385 samples from patients receiving lecanemab found that the markers tracking amyloid clearance were largely distinct from those tracking later cognitive decline. Brain-derived tau variants outperformed peripherally produced forms in distinguishing treated patients from untreated controls. The findings point toward multi-marker blood profiling as a route to understanding why identical diagnoses and identical therapies produce divergent outcomes.
Mighty Therapeutics and the University of Washington received $1 million as a Milestone 2 Awardee in the XPRIZE Healthspan competition for pilot work on elamipretide, a peptide that binds cardiolipin to support mitochondrial structure and function. The pilot results have not been disclosed; the team describes them as feasibility data intended to inform a randomized, placebo-controlled trial of muscle, cognitive and immune function in older adults. Elamipretide already holds FDA approval for Barth syndrome, making it one of the few mitochondria-directed therapies with a regulatory track record.
A hormone-free clitoral air-pulse device has launched in UK retail pharmacy with preliminary data linking sexual stimulation to menopausal symptom relief and increased vagal tone. In a 66-woman, four-week user study, 92.9% reported improvement in at least one of more than 34 possible symptoms, a threshold met without a control group. Separate observational work in 130 menopausal women associated regular sexual activity with higher heart rate variability, consistent with greater parasympathetic regulation.
A 12-week randomized, double-blind, vehicle-controlled trial of RLX-201, the active compound in Re-Q Longevity Face Serum, has been published in the Journal of Cosmetic Dermatology. Across 47 women aged 35 to 65 with moderate-to-severe photoaging, the company reports improvements in investigator-assessed firmness and cheek wrinkles of 21% from baseline at Week 12, with instrumented elastometry indicating improved viscoelastic properties from Week 8 onward and no adverse events in either arm.
Sironax has enrolled roughly half of the target population in its global Phase 2 FORGE-LM trial of SIR4156, an orally active allosteric NAMPT activator tested alongside semaglutide in adults with obesity. The primary endpoints center on fat mass and body composition rather than weight alone, with lean mass preservation among the secondary measures. Preclinical models reported preferential fat loss and reduced muscle atrophy, though the compound remains investigational and unapproved.
The Rhode Island Life Science Hub and Cognito Therapeutics have established the Rhode Island Brain Health Collaboratory, a statewide platform to evaluate and deploy Cognito's Spectris neuromodulation technology across health systems and research institutions. It is the third such regional collaboratory in Cognito's network, following partnerships in West Virginia and with Ochsner Health. The company states that Spectris AD holds FDA Breakthrough Device designation and that pivotal HOPE trial results are expected later in 2026.